This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Your saved search

Name of saved search:

Search terms:

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Jul 17;398(10296):212.

doi: 10.1016/S0140-6736(21)01556-7.

No authors listed

Published Erratum

No authors listed. Lancet. 2021.

. 2021 Jul 17;398(10296):212.

doi: 10.1016/S0140-6736(21)01556-7.

No abstract available

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Rosenstock J, et al. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Lancet. 2021. PMID: 34186022 Clinical Trial.